How Frequently Does Palmoplantar Psoriasis Affect the Palms And/or Soles? A Systematic Review and Meta-analysis

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2019 Dec 17

PMID 31839777

Citations 5

Authors

Zorica Sojevic Timotijevic

Goran Trajkovic

Janko Jankovic

Milijana Relic

Dragica doric

Danica Vukicevic

Goran Relic

Dragisa Rasic

Milan Filipovic

Slavenka Jankovic

Affiliations

Soon will be listed here.

Abstract

Introduction: Palmoplantar psoriasis (PPP) is a variant of psoriasis that affects the palms and/or soles. Although PPP is a disabling and therapeutically challenging condition, its epidemiology is poorly defined.

Aim: To assess the prevalence of PPP locations (palms, soles or both), and to analyse epidemiological and clinical characteristics of the disease.

Material And Methods: Two bibliographic databases (MEDLINE and SCOPUS) were used as data sources searched from inception to October 2017. The selection of articles was limited to human subjects and English or French languages.

Results: A search resulted in a total of 293 articles, out of which 24 were utilized for the current systematic review and 21 for meta-analysis. All listed studies comprised a total of 2083 patients with PPP, with more males than females. According to the results of meta-analysis, majority of patients had the highest prevalence of both palms and soles involvement (95% CI: 47-67), with an almost equal prevalence showing palmar (21%; 95% CI: 13-30) or plantar (20%; 95% CI: 12-29) involvement. The most prevalent type of PPP was plaque/hyperkeratotic, followed by the pustular type.

Conclusions: Almost three-fifths (59%) of all PPP patients had involvement of both palms and soles, while exclusive palmar or plantar involvement was seen in 21% and 20% of patients, respectively. Future research should be performed to elucidate basic epidemiological and clinical characteristics of PPP, which would be helpful for proper consideration of this condition.

Citing Articles

Onychoscopy in Palmoplantar Psoriasis: A Comparative Study of Nonpustular Palmoplantar Psoriasis and Palmoplantar Pustulosis.

Yorulmaz A Dermatol Pract Concept. 2024; 14(4).

PMID: 39652960 PMC: 11619982. DOI: 10.5826/dpc.1404a227.

Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.

Huang I, Wu P, Chiu H, Huang Y Am J Clin Dermatol. 2024; 25(3):347-358.

PMID: 38438782 DOI: 10.1007/s40257-024-00849-0.

Mepolizumab induced palmoplantar psoriasis: A case report.

Artosi F, Diluvio L, Vultaggio M, Campione E, Bianchi L World J Clin Cases. 2023; 11(26):6154-6158.

PMID: 37731552 PMC: 10507557. DOI: 10.12998/wjcc.v11.i26.6154.

Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness.

Nicolescu A, Ionescu M, Constantin M, Ancuta I, Ionescu S, Niculet E Life (Basel). 2022; 12(12).

PMID: 36556415 PMC: 9785802. DOI: 10.3390/life12122050.

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report.

Al Muqrin A, Alghamdi A, Alshaalan Z Clin Cosmet Investig Dermatol. 2022; 15:2129-2132.

PMID: 36217411 PMC: 9547619. DOI: 10.2147/CCID.S384990.

References

Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S . Levels of proelafin peptides in the sera of the patients with generalized pustular psoriasis and pustulosis palmoplantaris. Acta Derm Venereol. 2000; 80(2):102-5. View

Kumar B, Kumar R, Kaur I . Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle?. Int J Dermatol. 1997; 36(4):309-12. DOI: 10.1046/j.1365-4362.1997.00176.x. View

Kumar B, Sandhu K, Kaur I . Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar psoriasis. J Dermatol. 2005; 31(10):798-801. DOI: 10.1111/j.1346-8138.2004.tb00602.x. View

Brunasso A, Salvini C, Massone C . Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients. J Eur Acad Dermatol Venereol. 2009; 23(4):415-9. DOI: 10.1111/j.1468-3083.2008.03062.x. View

Adisen E, Tekin O, Gulekon A, Gurer M . A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol. 2009; 23(7):814-9. DOI: 10.1111/j.1468-3083.2009.03197.x. View

Haseena K, George S, Riyaz N, Sasidharanpillai S, Puthussery P . Methotrexate iontophoresis versus coal tar ointment in palmoplantar psoriasis: A pilot study. Indian J Dermatol Venereol Leprol. 2017; 83(5):569-573. DOI: 10.4103/ijdvl.IJDVL_185_16. View

Lior S, Grigory K, Pnina S, Joseph S, Felix P . Therapeutic hotline. Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis. Dermatol Ther. 2010; 23(5):556-60. DOI: 10.1111/j.1529-8019.2010.01361.x. View

Pettey A, Balkrishnan R, Rapp S, Fleischer A, Feldman S . Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003; 49(2):271-5. DOI: 10.1067/s0190-9622(03)01479-8. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

10.

Nistico S, Saraceno R, Stefanescu S, Chimenti S . A 308-nm monochromatic excimer light in the treatment of palmoplantar psoriasis. J Eur Acad Dermatol Venereol. 2006; 20(5):523-6. DOI: 10.1111/j.1468-3083.2006.01503.x. View

11.

Ravi Kumar B, Kaur I, Kumar B . Topical methotrexate therapy in palmoplantar psoriasis. Indian J Dermatol Venereol Leprol. 2010; 65(6):270-2. View

12.

Coleman W, Lowe N, David M, Halder R . Palmoplantar psoriasis: experience with 8-methoxypsoralen soaks plus ultraviolet A with the use of a high-output metal halide device. J Am Acad Dermatol. 1989; 20(6):1078-82. DOI: 10.1016/s0190-9622(89)70136-5. View

13.

Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A . Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2016; 76(1):70-80. DOI: 10.1016/j.jaad.2016.07.058. View

14.

Bissonnette R, Suarez-Farinas M, Li X, Bonifacio K, Brodmerkel C, Fuentes-Duculan J . Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris. PLoS One. 2016; 11(5):e0155215. PMC: 4859542. DOI: 10.1371/journal.pone.0155215. View

15.

Menter A, Griffiths C . Current and future management of psoriasis. Lancet. 2007; 370(9583):272-284. DOI: 10.1016/S0140-6736(07)61129-5. View

16.

Redon E, Bursztejn A, Loos C, Barbaud A, Schmutz J . [A retrospective efficacy and safety study of UVB-TL01 phototherapy and PUVA therapy in palmoplantar psoriasis]. Ann Dermatol Venereol. 2010; 137(10):597-603. DOI: 10.1016/j.annder.2010.06.016. View

17.

Venkatesan A, Aravamudhan R, Perumal S, Kannan R, Thirunavukkarasu V, Shukla S . Palmoplantar psoriasis- ahead in the race-a prospective study from a tertiary health care centre in South India. J Clin Diagn Res. 2015; 9(3):WC01-3. PMC: 4413136. DOI: 10.7860/JCDR/2015/11716.5669. View

18.

Farley E, Masrour S, McKey J, Menter A . Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009; 60(6):1024-31. DOI: 10.1016/j.jaad.2008.11.910. View

19.

Ammoury A, El Sayed F, Dhaybi R, Bazex J . Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Venereol. 2008; 22(3):392-3. DOI: 10.1111/j.1468-3083.2007.02344.x. View

20.

Chung J, Callis Duffin K, Takeshita J, Shin D, Krueger G, Robertson A . Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014; 71(4):623-32. PMC: 4165651. DOI: 10.1016/j.jaad.2014.04.063. View